Jeffrey T. Chang
University of Texas Health Science Center at Houston
GeneCancerInternal medicinePhenotypeOncologyGene expressionTranscriptomeGene expression profilingMesenchymal stem cellImmunologyChemotherapyMetastasisTriple-negative breast cancerComputer scienceCancer researchBreast cancerGeneticsBioinformaticsComputational biologyMedicineEpithelial–mesenchymal transitionBiologyCancer cell
158Publications
40H-index
9,042Citations
Publications 141
Newest
#1Kanchan Singh (University of Texas Health Science Center at Houston)H-Index: 2
#2Melissa Pruski (University of Texas Health Science Center at Houston)H-Index: 4
Last. Jennifer M. Bailey-Lundberg (University of Texas Health Science Center at Houston)
view all 12 authors...
Source
#1Aritro NathH-Index: 8
Last. Andrea BildH-Index: 17
view all 24 authors...
The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood. To understand the selection of factors driving heterogeneity before and through adaptation to treatment, we profile single-cell RNA-sequencing (scRNA-seq) transcriptomes of HGSOC tumors collected longitudinally during therapy. We analyze scRNA-seq data from two independent patient cohorts to reveal that HGSOC is driven by three archetypal phenotypes, defined as oncog...
Source
#1Piccolo (BYU: Brigham Young University)
#2Zachary E. Ence (BYU: Brigham Young University)H-Index: 2
Last. Andrea Bild (City of Hope National Medical Center)H-Index: 17
view all 5 authors...
Command-line software plays a critical role in biology research. However, processes for installing and executing software differ widely. The Common Workflow Language (CWL) is a community standard that addresses this problem. Using CWL, tool developers can formally describe a tools inputs, outputs, and other execution details in a manner that fosters use of shared computational methods and reproducibility of complex analyses. CWL documents can include instructions for executing tools inside softw...
Source
#1Daniel J. McGrail (University of Texas MD Anderson Cancer Center)H-Index: 17
#2Patrick G. Pilie (University of Texas MD Anderson Cancer Center)H-Index: 13
Last. Shiaw-Yih Lin (University of Texas MD Anderson Cancer Center)H-Index: 1
view all 16 authors...
Background High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic neoantigens. Despite recent pan-cancer approval of ICB treatment for any TMB-H tumor, as assessed by the targeted FoundationOne CDx assay in nine tumor types, the utility of this biomarker has not been fully demonstrated across all cancers. Patients and methods Data from over 10 000 pat...
5 CitationsSource
#1Xuan Liu (University of Texas Health Science Center at Houston)
#2Sara J. C. Gosline (Sage Bionetworks)H-Index: 12
Last. Jeffrey T. Chang (University of Texas Health Science Center at Houston)H-Index: 40
view all 8 authors...
Single-cell RNA sequencing (scRNA-Seq) is an emerging strategy for characterizing immune cell populations. Compared to flow or mass cytometry, scRNA-Seq could potentially identify cell types and activation states that lack precise cell surface markers. However, scRNA-Seq is currently limited due to the need to manually classify each immune cell from its transcriptional profile. While recently developed algorithms accurately annotate coarse cell types (e.g. T cells versus macrophages), making fin...
Source
#1Swarnima SinghH-Index: 3
Last. Jeffrey M. RosenH-Index: 96
view all 20 authors...
Immunosuppressive elements within the tumor microenvironment such as Tumor Associated Macrophages (TAMs) can present a barrier to successful anti-tumor responses by cytolytic T cells. We employed preclinical syngeneic p53 null mouse models of TNBC to develop a treatment regimen that harnessed the immunostimulatory effects of low-dose chemotherapy coupled with the pharmacologic inhibition of TAMs. Combination therapy was used to successfully treat several highly aggressive, claudin-low murine mam...
Source
#1Sahil SethH-Index: 35
#2Gaiane M. RauchH-Index: 14
Last. Stacy L. MoulderH-Index: 42
view all 13 authors...
Source
#2Clinton YamH-Index: 3
Last. Jeffrey T. ChangH-Index: 40
view all 23 authors...
Background: MpBC is a rare breast cancer subtype that is commonly triple-negative and associated with a diminished response to NAT in published retrospective data sets, prompting some clinicians to recommend surgical resection followed by adjuvant therapy. Methods: The ARTEMIS trial (NCT02276443) uses imaging response and molecular profiling to personalize NAT in early stage TNBC. Patients with sensitive disease after 4 cycles of AC receive standard taxane-based NAT as the second phase of NAT, w...
Source
#1Jason I. GriffithsH-Index: 6
Last. Andrea BildH-Index: 17
view all 18 authors...
Source
#1Aritro Nath (City of Hope National Medical Center)H-Index: 8
#1Nath A (City of Hope National Medical Center)
Last. Andrea Bild (City of Hope National Medical Center)H-Index: 17
view all 4 authors...
In the absence of reliable and effective prognostic biomarkers, endocrine therapy remains the standard of care for all advanced and metastatic estrogen receptor-positive (ER+) breast cancers. Attempts to develop biomarkers using the baseline tumor transcriptome or genome of advanced ER+ breast cancers have so far been unsuccessful due to predictive models with poor reproducibility in independent studies. Here we present an approach to develop a low-dimensional biomarker that estimates the risk o...
Source